HealZen Therapeutics has successfully completed the first patients enrollment for Phase I clinical trial of the innovative drug HZ-H08905, which was independently developed by the company. The trial was conducted at the First Affiliated Hospital, Zhejiang University School of Medicine. This is the first in-human clinical trial of HZ-H08905, which aims to evaluate its safety/tolerability, pharmacokinetic characteristics, and preliminary efficacy in the treatment of relapsed or refractory non-Hodgkin's lymphoma patients.

About HZ-H08905
HZ-H08905 is a novel oral small molecule dual-target inhibitor of CK1ε & PI3Kδ, independently developed by HealZen Therapeutics. It works by inhibiting CK1ε to block activation of the Wnt/β-Catenin pathway, as well as inhibiting PI3Kδ to block BCR, PI3K-Akt and other signaling pathways and play a synergistic anti-tumor role. In addition, the special mechanism of HZ-H08905 can effectively reduce the damage to normal epithelial cells caused by PI3Kδ inhibition. Preclinical studies have shown that HZ-H08905 has high activity and good safety against various hematologic and solid tumors. HZ-H08905 can be used as monotherapy or in combination with other anti-tumor drugs, aiming to provide new clinical treatment options for malignant hematologic and solid tumors.